Patient Perspectives on Non-Hodgkin Lymphoma: A Qualitative Study to Guide Selection of Clinical Trial Endpoints
Current Oncology · 17.07.2026 · 33 (7) · 427
DOI: 10.3390/curroncol33070427 ↗Kurz gefasst
Qualitative Studie in der Zeitschrift Current Oncology, online erschienen am 17.07.2026. Verfasst von Amy Clark und 4 weiteren Autor:innen. Beteiligte Einrichtung: PPD™ Evidera™ Patient-Centered Research, Thermo Fisher Scientific, London W6 8BJ, UK. Hauptthemen laut MEDLINE: Lymphoma, Non-Hodgkin. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi (France).
Abstract (Originalsprache)
The literature on the qualitative experiences of patients with non-Hodgkin lymphoma (NHL) is limited. Qualitative interviews were conducted to investigate participants’ experiences with two types of NHL (diffuse large B-cell lymphoma [n = 20] and mantle cell lymphoma [n = 10]) and evaluate the comprehensiveness of patient-reported outcome (PRO) measures. Fatigue, tiredness, body aches, night sweats, lethargy, headache, appetite loss, altered taste, and weakness were the most frequent and bothersome symptoms. Key impacts were decreased physical performance, restricted activity, sadness, distress, fear of recurrence, and worry about future. Most participants expressed positive opinions about the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 (EORTC QLQ-C30) (n = 22/28), EORTC QLQ-NHL-High Grade Module 29 (EORTC QLQ-NHL-HG29) (n = 12/16), EORTC QLQ-NHL-Low Grade Module 20 (EORTC QLQ-NHL-LG20) (n = 8/12), and Functional Assessment of Cancer Therapy–Lymphoma (FACT-Lym) (n = 10/14), considering them relevant to their experiences (22/27, 13/15, 9/13, and 10/12, respectively). All measures adequately captured their experiences with NHL (QLQ-C30: n = 26/26, NHL-HG29: n = 14/14, NHL-LG20: n = 11/11, and FACT-Lym: n = 12/13). These findings provide a valuable framework for informing the selection of appropriate PRO measures in NHL clinical trials and identifying potentially meaningful trial endpoints.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- PPD™ Evidera™ Patient-Centered Research, Thermo Fisher Scientific, London W6 8BJ, UK.
- Sanofi, 1105 BP Amsterdam, The Netherlands.
- Sanofi, Reading RG6 1PT, UK.
ORCID-Profile: Sophie Van Tomme
Förderung
- Sanofi (France)
Zitieren
APA
Clark, A., Tomme, S. V., Hetherington, L., Barbosa, C. D., & Cordero, P. (2026). Patient Perspectives on Non-Hodgkin Lymphoma: A Qualitative Study to Guide Selection of Clinical Trial Endpoints. Current Oncology, 33(7), 427. https://doi.org/10.3390/curroncol33070427
Vancouver
Clark A, Tomme SV, Hetherington L, Barbosa CD, Cordero P. Patient Perspectives on Non-Hodgkin Lymphoma: A Qualitative Study to Guide Selection of Clinical Trial Endpoints. Current Oncology. 2026;33(7):427. doi:10.3390/curroncol33070427
BibTeX
@article{Clark2026,
author = {Clark, Amy and Tomme, Sophie Van and Hetherington, Lucinda and Barbosa, Carla Dias and Cordero, Paul},
title = {Patient Perspectives on Non-Hodgkin Lymphoma: A Qualitative Study to Guide Selection of Clinical Trial Endpoints},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {7},
pages = {427},
doi = {10.3390/curroncol33070427}
}
EUVIMED